Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Inflammation
Published in: Journal of Inflammation 1/2008

Open Access 01-12-2008 | Hypothesis

Does CD4+CD25+foxp3+ cell (Treg) and IL-10 profile determine susceptibility to immune reconstitution inflammatory syndrome (IRIS) in HIV disease?

Authors: Esaki Muthu Shankar, Ramachandran Vignesh, Vijayakumar Velu, Kailapuri G Murugavel, Ramalingam Sekar, Pachamuthu Balakrishnan, Charmaine AC Lloyd, Shanmugam Saravanan, Suniti Solomon, Nagalingeswaran Kumarasamy

Published in: Journal of Inflammation | Issue 1/2008

Login to get access

Abstract

HIV-specific T-lymphocyte responses that underlie IRIS are incomplete and largely remain hypothetical. Of the several mechanisms presented by the host to control host immunological damage, Treg cells are believed to play a critical role. Using the available experimental evidence, it is proposed that enormous synthesis of conventional FoxP3- Th cells (responsive) often renders subjects inherently vulnerable to IRIS, whereas that of natural FoxP3+ Treg cell synthesis predominate among subjects that may not progress to IRIS. We also propose that IRIS non-developers generate precursor T-cells with a high avidity to generate CD4+CD25+FoxP3+ Tregs whereas IRIS developers generate T-cells of intermediate avidity yielding Th0 cells and effector T-cells to mediate the generation of proinflammatory cytokines in response to cell-signaling factors (IL-2, IL-6 etc.). Researchers have shown that IL-10 Tregs (along with TGF-β, a known anti-inflammatory cytokine) limit immune responses against microbial antigens in addition to effectively controlling HIV replication, the prime objective of HAART. Although certain technical limitations are described herein, we advocate measures to test the role of Tregs in IRIS.
Literature
1.
Kumarasamy N, Chaguturu S, Mayer KH, Solomon S, Yepthomi HT, Balakrishnan P: et al., Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr. 2004, 37: 1574-1576. 10.1097/00126334-200412150-00007.PubMedCrossRef
2.
Keane NM, Price P, Lee S, Almeida CA, Stone SF, James I, French MA: Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy. HIV Med. 2004, 5: 407-414. 10.1111/j.1468-1293.2004.00245.x.PubMedCrossRef
3.
Stone SF, Price P, Brochier J, French MA: Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpes virus-associated immune restoration disease after start of highly active antiretroviral therapy. J Infect Dis. 2001, 184: 1073-1077. 10.1086/323599.PubMedCrossRef
4.
Koval CE, Gigliotti F, Nevins D, Demeter LM: Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis. 2002, 35: 491-493. 10.1086/341974.PubMedCrossRef
5.
Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G: Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis. 2006, 43: 1069-1073. 10.1086/507895.PubMedCrossRef
6.
Lawn SD, Bicanic TA, Macallan DC: Pyomyositis and cutaneous abscesses due to Mycobacterium avium : an immune reconstitution manifestation in a patient with AIDS. Clin Infect Dis. 2004, 38: 461-463. 10.1086/381033.PubMedCrossRef
7.
Sereti I, Sarlis NJ, Arioglu E, Turner ML, Mican JM: Alopecia universalis and Graves' disease in the setting of immune restoration after highly active antiretroviral therapy. AIDS. 2001, 15: 138-140. 10.1097/00002030-200101050-00026.PubMedCrossRef
8.
Mirmirani P, Maurer TA, Herndier B, McGrath M, Weinstein MD, Berger TG: Sarcoidosis in a patient with AIDS: a manifestation of immune restoration syndrome. J Am Acad Dermatol. 1999, 41: 285-286. 10.1016/S0190-9622(99)70364-6.PubMedCrossRef
9.
Lawn SD, Checkley A, Wansbrough-Jones MH: Acute bilateral parotitis caused by Mycobacterium scrofulaceum : immune reconstitution disease in a patient with AIDS. Sex Transm Infect. 2005, 81: 517-518. 10.1136/sti.2005.014993.PubMedPubMedCentralCrossRef
10.
Taylor CL, Subbarao V, Gayed S, Ustianowski AP: Immune reconstitution syndrome to Strongyloides stercoralis infection. AIDS. 2007, 21: 649-650.PubMedCrossRef
11.
Shankar EM, Vignesh R, Murugavel KG, Balakrishnan P, Lloyd CA, Sekar R, Solomon S, Kumarasamy N: Immune reconstitution inflammatory syndrome in association with HIV/AIDS and tuberculosis: Views over hidden possibilities. AIDS Res Ther. 2007, 4: 29-10.1186/1742-6405-4-29.PubMedPubMedCentralCrossRef
12.
Shelburne SA, Montes M, Hamill RJ: Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 2006, 57: 167-170. 10.1093/jac/dki444.PubMedCrossRef
13.
Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, Gicquel B, Vicaut E, Lagrange PH, Sereni D, Autran B: Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS. 2006, 20: F1-F7.PubMedCrossRef
14.
Kumarasamy N, Vallabhaneni S, Flanigan TP, Mayer KH, Solomon S: Clinical profile of HIV in India. Indian J Med Res. 2005, 121: 377-394.PubMed
15.
Shelburne S, Visnegarwala F, Darcourt J, Graviss E, Giordano T, White AC, Hamill RJ: Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005, 19: 399-406. 10.1097/01.aids.0000161769.06158.8a.PubMedCrossRef
16.
Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, Sillers M, Mitsuyasu RT, Kilby JM: Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest. 1999, 103: 1391-1398. 10.1172/JCI5863.PubMedPubMedCentralCrossRef
17.
Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debré P, Leibowitch J: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997, 277: 112-116. 10.1126/science.277.5322.112.PubMedCrossRef
18.
Narendran G, Swaminathan S, Sathish S, Rajasekaran S: Immune reconstitution syndrome in a child with TB and HIV. Indian J Pediatr. 2006, 73: 627-629. 10.1007/BF02759931.PubMedCrossRef
19.
Swaminathan S, Padmapriya C, Narendran G, Thomas B, Anand S, Rajalakshmi A: Immune reconstitution syndrome following initiation of antiretroviral therapy in HIV and multidrug resistant tuberculosis. Indian J Chest Dis Allied Sci. 2005, 47: 299-304.PubMed
20.
Wendland T, Furrer H, Vernazza PL, Frutig K, Christen A, Matter L, MPichler WJ: HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. AIDS. 1999, 13: 1857-1862. 10.1097/00002030-199910010-00007.PubMedCrossRef
21.
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995, 155: 1151-1164.PubMed
22.
Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T: Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001, 182: 18-32. 10.1034/j.1600-065X.2001.1820102.x.PubMedCrossRef
23.
Shevach EM: Suppressor T cells: Rebirth, function and homeostasis. Curr Biol. 2000, 10: R572-R575. 10.1016/S0960-9822(00)00617-5.PubMedCrossRef
24.
Powrie F, Correa-Oliveira R, Mauze S, Coffman RL: Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med. 1994, 179: 589-600. 10.1084/jem.179.2.589.PubMedCrossRef
25.
Maloy KJ, Powrie F: Regulatory T cells in the control of immune pathology. Nat Immunol. 2001, 2: 816-822. 10.1038/ni0901-816.PubMedCrossRef
26.
Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F: An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999, 190: 995-1004. 10.1084/jem.190.7.995.PubMedPubMedCentralCrossRef
27.
Read S, Malmstrom V, Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000, 192: 295-302. 10.1084/jem.192.2.295.PubMedPubMedCentralCrossRef
28.
Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S: Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000, 192: 303-310. 10.1084/jem.192.2.303.PubMedPubMedCentralCrossRef
29.
Seddon B, Mason D: Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor b and interleukin 4 in the prevention of autoimmune thryroiditis in rats by peripheral CD4+ CD45RC- cells and CD4+ CD8- thymocytes. J Exp Med. 1999, 89: 279-288. 10.1084/jem.189.2.279.CrossRef
30.
Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL: A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med. 1996, 183: 2669-2674. 10.1084/jem.183.6.2669.PubMedCrossRef
31.
Nakamura K, Kitani A, Strober W: Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001, 194: 629-644. 10.1084/jem.194.5.629.PubMedPubMedCentralCrossRef
32.
Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA: CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA. 2003, 100: 10878-10883. 10.1073/pnas.1834400100.PubMedPubMedCentralCrossRef
33.
Oida T, Zhang X, Goto M, Hachimura S, Totsuka M, Kaminogawa S, Weiner HL: CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol. 2003, 170: 2516-2522.PubMedCrossRef
34.
Sundstedt A, O'Neill EJ, Nicolson KS, Wraith DC: Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J Immunol. 2003, 170: 1240-1248.PubMedCrossRef
35.
Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997, 389: 737-742. 10.1038/39614.PubMedCrossRef
36.
Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK: Type 1 T regulatory cells. Immunol Rev. 2001, 182: 68-79. 10.1034/j.1600-065X.2001.1820105.x.PubMedCrossRef
37.
Buer J, Lanoue A, Franzke A, Garcia C, von Boehmer H, Sarukhan A: Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. J Exp Med. 1998, 187: 177-183. 10.1084/jem.187.2.177.PubMedPubMedCentralCrossRef
38.
Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O'Garra A: In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 2002, 195: 603-616. 10.1084/jem.20011629.PubMedPubMedCentralCrossRef
39.
Pontoux C, Banz A, Papiernik M: Natural CD4 CD25(+) regulatory T cells control the burst of superantigen-induced cytokine production: the role of IL-10. Int Immunol. 2002, 14: 233-239. 10.1093/intimm/14.2.233.PubMedCrossRef
40.
Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, Boonstra A, Barthlott T, Stockinger B, Wraith DC, O'Garra A: IL-10 secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occuring CD4+CD25+ regulatory T cells. J Immunol. 2004, 172: 5986-5993.PubMedCrossRef
41.
Weiner HL: Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today. 1997, 18: 335-343. 10.1016/S0167-5699(97)01053-0.PubMedCrossRef
42.
Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF: Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol. 2004, 78: 2454-2459. 10.1128/JVI.78.5.2454-2459.2004.PubMedPubMedCentralCrossRef
43.
Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, Dascher CC, Berezovskaya A, Rousset D, Reynes JM, Goldfeld AE: IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest. 2000, 105: 1317-1325. 10.1172/JCI9918.PubMedPubMedCentralCrossRef
44.
Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, Daucher M, Planta M, McGlaughlin M, Jackson R, Ziegler SF, Fauci AS: CD25+CD4+ regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4 and CD8 HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med. 2004, 200: 331-343. 10.1084/jem.20032069.PubMedPubMedCentralCrossRef
45.
Oswald-Richter K, Grill SM, Shariat N, Leelawong M, Sundrud MS, Haas DW, Unutmaz D: HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol. 2004, 2: E198-10.1371/journal.pbio.0020198.PubMedPubMedCentralCrossRef
46.
Xu D, Liu H, Komai-Koma M, Campbell C, McSharry C, Alexander J, Liew FY: CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J Immunol. 2003, 170: 394-399.PubMedCrossRef
47.
Sher A, Coffman RL: Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu Rev Immunol. 1992, 10: 385-409. 10.1146/annurev.iy.10.040192.002125.PubMedCrossRef
48.
O'Garra A, Robinson D: Development and function of T helper 1 cells. Adv Immunol. 2004, 83: 133-162.PubMedCrossRef
49.
O'Garra A: Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 1998, 8: 275-283. 10.1016/S1074-7613(00)80533-6.PubMedCrossRef
50.
Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001, 19: 683-765. 10.1146/annurev.immunol.19.1.683.PubMedCrossRef
Metadata
Title
Does CD4+CD25+foxp3+ cell (Treg) and IL-10 profile determine susceptibility to immune reconstitution inflammatory syndrome (IRIS) in HIV disease?
Authors
Esaki Muthu Shankar
Ramachandran Vignesh
Vijayakumar Velu
Kailapuri G Murugavel
Ramalingam Sekar
Pachamuthu Balakrishnan
Charmaine AC Lloyd
Shanmugam Saravanan
Suniti Solomon
Nagalingeswaran Kumarasamy
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2008
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-5-2

Other articles of this Issue 1/2008

Journal of Inflammation 1/2008 Go to the issue

Research

Bioavailable constituents/metabolites of pomegranate (Punica granatum L) preferentially inhibit COX2 activity ex vivo and IL-1beta-induced PGE2 production in human chondrocytes i n vitro

Research

Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription

Research

The tripeptide feG inhibits leukocyte adhesion

Research

Cellular and molecular mechanisms of cigarette smoke-induced lung damage and prevention by vitamin C

Research

Does carbon monoxide treatment alter cytokine levels after endotoxin infusion in pigs? A randomized controlled study

Research

Anti-oxidant inhibition of hyaluronan fragment-induced inflammatory gene expression
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits